We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed) Carbidopa and levodopa tablets, USP 25 mg/100mg (ScieGen)
Section 19A approved medicine
(Approval lapsed) Carbidopa and levodopa tablets, USP 25 mg/100mg (ScieGen)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 730 109 715 16
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
KINSON levodopa 100 mg with carbidopa (as monohydrate) 25 mg tablet bottle - ARTG 49481
Indication(s)
The treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. Carbidopa and levodopa tablets frequently are helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.
Images
